Three million people worldwide are taking the new, heavily advertised anti-cholesterol drugs Zetia and Vytorin, despite a lack of clinical evidence that they reduce cardiovascular disease or heart attacks, or help patients live longer. Vytorin and Zetia brought in $5.2 billion last year for Merck and Schering-Plough, placing them among the best-selling drugs in the world. The Food and Drug Administration approves many drugs based on whether they perform a specific action, like lowering cholesterol, without requiring long-term trials on whether they extend life or lower disease risks. Other FDA-approved drugs have been found to be ineffective or even dangerous.
Best-Selling Cholesterol Drugs Found Ineffective
A unanimous Court on June 12 made it easier for families to use the Americans with Disabilities...
Health Secretary Robert F. Kennedy Jr. has fired all 17 members of a committee that advises...
US lawmakers on both sides of the aisle are raising concerns and seeking investigations in the...
A public health alert has been issued for organic ground beef products that reportedly could be...
